A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet

International Journal of Obesity

Volumn 40, Issue 6, 2016, Pages 964-972

  Mammi, C ^a   Marzolla, V ^a   Armani, A ^a   Feraco, A ^a   Antelmi, A ^a   Maslak, E ^b   Chlopicki, S ^b   Cinti, F ^a,c   Hunt, H ^d   Fabbri, A ^e   Caprio, M ^a,f  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d Università Politecnica Delle Marche ^*  (United States)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f San Raffaele Roma Open University   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CORT 118335; DEXAMETHASONE; GLUCOCORTICOID ANTAGONIST; GLUCOCORTICOID RECEPTOR; LEPTIN; MIFEPRISTONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; UNCLASSIFIED DRUG; CORT118335; THYMINE;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BROWN ADIPOCYTE; CONTROLLED STUDY; DIET INDUCED OBESITY; FAT MASS; FATTY LIVER; FEMALE; FOOD INTAKE; GLUCOSE TOLERANCE; HYPERTROPHY; IMPAIRED GLUCOSE TOLERANCE; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN EXPRESSION; SUBCUTANEOUS FAT; WEIGHT GAIN; WHITE ADIPOSE TISSUE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY WEIGHT GAIN; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS;

ADIPOSE TISSUE; ANIMALS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FEMALE; MALE; MICE; MICE, INBRED C57BL; MIFEPRISTONE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, GLUCOCORTICOID; THYMINE; WEIGHT GAIN;

EID: 84961390135     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2016.13     Document Type: Article

References (35)

1. Dallman MF, Pecoraro N, Akana SF, La Fleur SE, Gomez F, Houshyar H et al. Chronic stress and obesity: A new view of "comfort food". Proc Natl Acad Sci USA 2003; 100: 11696-11701.
2. Warne JP, Akana SF, Ginsberg AB, Horneman HF, Pecoraro NC, Dallman MF. Disengaging insulin from corticosterone: roles of each on energy intake and disposition. Am J Physiol Regul Integr Comp Physiol 2009; 296: R1366-R1375.
3. Geer EB, Shen W, Gallagher D, Punyanitya M, Looker HC, Post KD et al. MRI assessment of lean and adipose tissue distribution in female patients with Cushing's disease. Clin Endocrinol (Oxf) 2010; 73: 469-475.
4. Geer EB, Shen W, Strohmayer E, Post KD, Freda PU. Body composition and cardiovascular risk markers after remission of Cushing's disease: A prospective study using whole-body MRI. J Clin Endocrinol Metab 2012; 97: 1702-1711.
5. Langley SC, York DA. Effects of antiglucocorticoid RU 486 on development of obesity in obese fa/fa Zucker rats. Am J Physiol 1990; 259: R539-R544.
6. Livingstone DE, Kenyon CJ, Walker BR. Mechanisms of dysregulation of 11 betahydroxysteroid dehydrogenase type 1 in obese Zucker rats. J Endocrinol 2000; 167: 533-539.
7. Chapman AB, Knight DM, Ringold GM. Glucocorticoid regulation of adipocyte differentiation: hormonal triggering of the developmental program and induction of a differentiation-dependent gene. J Cell Biol 1985; 101: 1227-1235.
8. Gathercole LL, Bujalska IJ, Stewart PM, Tomlinson JW. Glucocorticoid modulation of insulin signaling in human subcutaneous adipose tissue. J Clin Endocrinol Metab 2007; 92: 4332-4339.
9. Harrell CS, Gillespie CF, Neigh GN. Energetic stress: The reciprocal relationship between energy availability and the stress response. Physiol Behav 2015; S0031-9384: 30139-6.
10. Feraco A, Armani A, Mammi C, Fabbri A, Rosano GM, Caprio M. Role of mineralocorticoid receptor and renin-angiotensin-aldosterone system in adipocyte dysfunction and obesity. J Steroid Biochem Mol Biol 2013; 137: 99-106.
11. Rondinone CM, Rodbard D, Baker ME. Aldosterone stimulated differentiation of mouse 3T3-L1 cells into adipocytes. Endocrinology 1993; 132: 2421-2426.
12. Zennaro MC, Le Menuet D, Viengchareun S, Walker F, Ricquier D, Lombes M. Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. J Clin Invest 1998; 101: 1254-1260.
13. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007; 21: 2185-2194.
14. Hoppmann J, Perwitz N, Meier B, Fasshauer M, Hadaschik D, Lehnert H et al. The balance between gluco-and mineralo-corticoid action critically determines inflammatory adipocyte responses. J Endocrinol 2010; 204: 153-164.
15. Funder J, Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 1996; 137: 5264-5268.
16. Funder JW. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev 2005; 10: 15-22.
17. Armani A, Marzolla V, Rosano G, Caprio M. Mineralocorticoid vs glucocorticoid receptors: solo players or team mates in the control of adipogenesis? Int J Obes (Lond) 2014; 38: 1580-1581.
18. Lee MJ, Fried SK. The glucocorticoid receptor, not the mineralocorticoid receptor, plays the dominant role in adipogenesis and adipokine production in human adipocytes. Int J Obes (Lond) 2014; 38: 1228-1233.
19. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008; 117: 2253-2261.
20. Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009; 84: 164-172.
21. Armani A, Cinti F, Marzolla V, Morgan J, Cranston GA, Antelmi A et al. Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in highfat-diet-fed mice. FASEB J 2014; 28: 3745-3757.
22. Hunt HJ, Ray NC, Hynd G, Sutton J, Sajad M, O'Connor E et al. Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapineinduced weight gain model in the rat. Bioorg Med Chem Lett 2012; 22: 7376-7380.
23. Zorrilla EP, Sanchez-Alavez M, Sugama S, Brennan M, Fernandez R, Bartfai T et al. Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency. Proc Natl Acad Sci USA 2007; 104: 11097-11102.
24. Marinozzi F, Marinozzi A, Bini F, Zuppante F, Pecci R, Bedini R. Variability of morphometric parameters of human trabecular tissue from coxo-arthritis and osteoporotic samples. Ann Ist Super Sanita 2012; 48: 19-25.
25. Soukas A, Socci ND, Saatkamp BD, Novelli S, Friedman JM. Distinct transcriptional profiles of adipogenesis in vivo and in vitro. J Biol Chem 2001; 276: 34167-34174.
26. Caprio M, Antelmi A, Chetrite G, Muscat A, Mammi C, Marzolla V et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 2011; 152: 113-125.
27. Collins S, Martin TL, Surwit RS, Robidoux J. Genetic vulnerability to diet-induced obesity in the C57BL/6 J mouse: physiological and molecular characteristics. Physiol Behav 2004; 81: 243-248.
28. Hashimoto T, Igarashi J, Hasan AU, Ohmori K, Kohno M, Nagai Y et al. Mifepristone promotes adiponectin production and improves insulin sensitivity in a mouse model of diet-induced-obesity. PLoS One 2013; 8: e79724.
29. van den Heuvel JK, Boon MR, Mol IM, van de Velde N, Koorneef LL, Hunt H et al. A novel mixed glucocorticoid/mineralocorticoid receptorselective modulator reducesobesityand adipose tissue and liver inflammation. Oral presentation COSTADMIRE Annual Meeting, Padua, Italy, October 16th-17th, 2014.
30. Seale P, Conroe HM, Estall J, Kajimura S, Frontini A, Ishibashi J et al. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest 2011; 121: 96-105.
31. Wada T, Kenmochi H, Miyashita Y, Sasaki M, Ojima M, Sasahara M et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 2010; 151: 2040-2049.
32. Marroqui L, Gonzalez A, Neco P, Caballero-Garrido E, Vieira E, Ripoll C et al. Role of leptin in the pancreatic beta-cell: effects and signaling pathways. J Mol Endocrinol 2012; 49: R9-17.
33. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999; 98: 115-124.
34. Kleiner S, Mepani RJ, Laznik D, Ye L, Jurczak MJ, Jornayvaz FR et al. Development of insulin resistance in mice lacking PGC-1alpha in adipose tissues. Proc Natl Acad Sci USA 2012; 109: 9635-9640.
35. Choo HJ, Kim JH, Kwon OB, Lee CS, Mun JY, Han SS et al. Mitochondria are impaired in the adipocytes of type 2 diabetic mice. Diabetologia 2006; 49: 784-791.